In the preceding three months, 7 analysts have released ratings for Kymera Therapeutics KYMR, presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.29, a high estimate of $65.00, and a low estimate of $36.00. Witnessing a positive shift, the current average has risen by 26.36% from the previous average price target of $39.80.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Kymera Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jeff Jones | Oppenheimer | Raises | Outperform | $56.00 | $52.00 |
| Faisal Khurshid | Leerink Partners | Announces | Outperform | $60.00 | - |
| Andy Chen | Wolfe Research | Announces | Outperform | $65.00 | - |
| James Quigley | Morgan Stanley | Raises | Equal-Weight | $45.00 | $34.00 |
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $38.00 | $30.00 |
| Jeff Jones | Oppenheimer | Maintains | Outperform | $52.00 | $52.00 |
| Kalpit Patel | B. Riley Securities | Raises | Neutral | $36.00 | $31.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kymera Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Kymera Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Kymera Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Kymera Therapeutics analyst ratings.
Delving into Kymera Therapeutics's Background
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Key Indicators: Kymera Therapeutics's Financial Health
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Kymera Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 55.33%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Kymera Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -163.98%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kymera Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.97%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
